Evidence map›Paper›PMID 39051250›Full record

ReviewGeriatrics (Basel, Switzerland)2024

Alzheimer's Disease: Cellular and Pharmacological Aspects.

Gonzalo Emiliano Aranda-Abreu, Fausto Rojas-Durán, María Elena Hernández-Aguilar, Deissy Herrera-Covarrubias, Lizbeth Donají Chí-Castañeda, María Rebeca Toledo-Cárdenas, Jorge Manuel Suárez-Medellín

Abstract readReview
In one paragraph

Review in Geriatrics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gonzalo Emiliano Aranda-AbreuInstituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91192, Mexico.ORCID 0000-0001-8519-5473
Fausto Rojas-DuránInstituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91192, Mexico.ORCID 0000-0003-4497-0909
María Elena Hernández-AguilarInstituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91192, Mexico.ORCID 0000-0002-1617-5636
Deissy Herrera-CovarrubiasInstituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91192, Mexico.
Lizbeth Donají Chí-CastañedaInstituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91192, Mexico.ORCID 0000-0002-2094-5787
María Rebeca Toledo-CárdenasInstituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91192, Mexico.ORCID 0000-0003-1273-4944
Jorge Manuel Suárez-MedellínInstituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91192, Mexico.ORCID 0000-0001-6676-5143

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease was described more than 100 years ago and despite the fact that several molecules are being tested for its treatment, which are in phase III trials, the disease continues to progress. The main problem is that these molecules function properly in healthy neurons, while neuronal pathology includes plasma membrane disruption, malfunction of various organelles, and hyperphosphorylation of Tau and amyloid plaques. The main objective of this article is the discussion of a neuronal restoration therapy, where molecules designed for the treatment of Alzheimer's disease would probably be more effective, and the quality of life of people would be better.

Indexed as

Alzheimercelldrugs

Identifiers

PMID39051250
PMCPMC11270425

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.